Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications

Hormone receptor-positive breast cancer (HR+ BC) accounts for approximately 75% of new BC diagnoses. Despite the undisputable progresses obtained in the treatment of HR+ BC in recent years, primary or acquired resistance to endocrine therapies still represents a clinically relevant issue, and is lar...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cells
Autors principals: Zattarin, Emma, Leporati, Rita, Ligorio, Francesca, Lobefaro, Riccardo, Vingiani, Andrea, Pruneri, Giancarlo, Vernieri, Claudio
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2020
Matèries:
Review
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7764472/
https://ncbi.nlm.nih.gov/pubmed/33316954
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells9122644
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars